Topotecan Hydrochloride Injection, Powder, Lyophilized, For Solution
FDA Label NDC 45963-615

38 label sections · Submitted to the FDA by Actavis Pharma, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Actavis Pharma, Inc. for the product Topotecan Hydrochloride (NDC 45963-615). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: myelosuppression, 1.1 ovarian cancer, 1.2 small cell lung cancer, 1.3 cervical cancer, 2.1 important safety information, 2.2 recommended dosage for ovarian cancer, 2.3 recommended dosage for small cell lung cancer (sclc), 2.4 recommended dosage for cervical cancer, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.